Overview

Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test)

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
To compare the bioavailability of a single 400 mg dose of certolizumab pegol solution (2 x 200mg subcutaneous injections) injected either by a pre-filled syringe (reference) or by an auto-injection device (test).
Phase:
Phase 1
Details
Lead Sponsor:
UCB Pharma
Treatments:
Certolizumab Pegol